ELUVIA: DES en territorio femoropoplíteo con lesiones complejas

ELUVIA: DES in Complex Femoropopliteal Lesions

Paclitaxel-eluting stent Eluvia showed promising results after two years with a revascularization freedom rate of 80% despite the fact that these were complex femoropopliteal lesions. As the safety of paclitaxel-eluting devices becomes more consistent, more studies on its efficacy are being published. Back in 2018, the safety of paclitaxel-eluting balloons and stents was under scrutiny<a href="https://solaci.org/en/2021/06/12/eluvia-des-in-complex-femoropopliteal-lesions/" title="Read more" >...</a>

EuroPCR 2021 | CASTLE: Orsiro vs Xience Guided by Intravascular Imaging

According to the CASTLE trial, the Orsino stent—a biodegradable, ultrathin, sirolimus-eluting stent—provides the same results at 12 months as Xience in angioplasty guided by intravascular imaging. This research was presented at the virtual EuroPCR 2021 Congress. Previous studies (BIOSTEMI and BIOFLOW V) showed that Orsiro was superior to Xience in reducing target-lesion revascularization. However, the reason behind this<a href="https://solaci.org/en/2021/05/29/europcr-2021-castle-orsiro-vs-xience-guided-by-intravascular-imaging/" title="Read more" >...</a>

EuroPCR 2021 | EBC MAIN: Provisional Stenting vs. Systematic Dual Stenting in Left Main Coronary Artery

Treating the left main coronary artery with provisional stenting was non-inferior to systematic dual stenting in the EBC MAIN trial, presented at EuroPCR 2021 and simultaneously published in the European Heart Journal. The composite primary endpoint of death, infarction, and target-lesion revascularization was 14.7% for provisional stenting vs. 17.7% for systematic dual stenting (hazard ratio:<a href="https://solaci.org/en/2021/05/29/europcr-2021-ebc-main-provisional-stenting-vs-systematic-dual-stenting-in-left-main-coronary-artery/" title="Read more" >...</a>

EuroPCR 2021 | Ultrathin Struts Consolidate as Next DES Development

According to this recent meta-analysis of randomized studies, ultrathin strut devices are associated with lower rates of target vessel failure vs. 2nd generation drug eluting stents (DES). This advantage was driven by fewer clinically justified reinterventions.  This study was published in the European Heart Journal and simultaneously presented at EuroPCR 2021 Scientific Sessions. Ultrathin struts<a href="https://solaci.org/en/2021/05/26/europcr-2021-ultrathin-struts-consolidate-as-next-des-development/" title="Read more" >...</a>

EuroPCR 2021 | FUTURE II: las plataformas bioabsorbibles vuelven recargadas

EuroPCR 2021 | FUTURE II: Bioresorbable Scaffolds Reloaded

A new sirolimus-eluting bioresorbable scaffold with far thinner struts resulted non inferior to the Xience as to the end point of angiographic in-segment late loss (LL) powered for noninferiority testing. Even though this is a small study with angiographic end points, it might be the first step towards the return of bioresorbable scaffolds.  Read also:<a href="https://solaci.org/en/2021/05/26/europcr-2021-future-ii-bioresorbable-scaffolds-reloaded/" title="Read more" >...</a>

Balancear el riesgo de sangrado vs trombótico para definir el tiempo de doble antiagregación

Very Short Dual Antiplatelet Therapy after Complex PCI

The 1-month outcomes of dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy were comparable to 12-month DAPT in patients with both simple and complex PCI. There was no significant interaction between DAPT period and procedure difficulty.  This is a post hoc study of the STOPDAPT-2 that looked at the complex PCI patient subgroup.   It is<a href="https://solaci.org/en/2021/05/24/very-short-dual-antiplatelet-therapy-after-complex-pci/" title="Read more" >...</a>

SAFE-PAD: Dispositivos liberadores de paclitaxel en enfermedad periférica

ACC 2021 | SAFE-PAD: Paclitaxel-Eluting Devices in Peripheral Disease

This work was conducted alongside the US Food and Drug Administration (FDA) to investigate the association between all-cause mortality and paclitaxel-eluting devices in peripheral vascular disease. According to data from SAFE-PAD, presented at the American College of Cardiology (ACC) 2021 Congress and simultaneously published in JAMA, there is no increase in mortality compared with conventional<a href="https://solaci.org/en/2021/05/19/acc-2021-safe-pad-paclitaxel-eluting-devices-in-peripheral-disease/" title="Read more" >...</a>

Tasa de stroke post cirugía vs angioplastia coronaria en un análisis de más de 10.000 pacientes

How to Discontinue Antiplatelet Therapy Prior Non-Cardiac Surgery

Both the indication and discontinuation of antiplatelet therapy to balance ischemic-bleeding risks has been left to physician criterion.  However, leaving the decision to one single specialist might not be the best. This is when the team’s role becomes essential.  This study looked at the advantages consensus decision-making amongst clinicians, surgeons and anesthesiologists to continue or<a href="https://solaci.org/en/2021/05/03/how-to-discontinue-antiplatelet-therapy-prior-non-cardiac-surgery/" title="Read more" >...</a>

Bilateral Distal Transradial Access for Chronic Total Occlusion Recanalization and Multivessel Coronary Disease Percutaneous Intervention

[APT Medical Sponsored Clinical Case] Bilateral Distal Transradial Access for Chronic Total Occlusion Recanalization and Multivessel Coronary Disease Percutaneous Intervention

Introduction Chronic total occlusion (CTO) represents the most challenging setting for percutaneous coronary intervention (PCI) and multivessel coronary disease (MCD) is often treated in a staggered manner and in a deferred procedure. Although transfemoral is one of the common access site, the transradial access (TRA) has been used with similar procedural success [1]. The distal<a href="https://solaci.org/en/2021/04/28/apt-medical-sponsored-clinical-case-bilateral-distal-transradial-access-for-chronic-total-occlusion-recanalization-and-multivessel-coronary-disease-percutaneous-intervention/" title="Read more" >...</a>

$reserva fraccional de flujo$

The Future of Prevention? Stenting Vulnerable Fractional FFR Negative Lesions

For many patients, the first symptom of heart disease is acute MI, or even sudden death.  Changes in lifestyle and optimal medical treatment (OMT) are vital to the prevention of serious events, but we cannot help wondering whether preventive stenting might do it.  Intravascular ultrasound (IVUS), optical coherence tomography (OCT), NIRS near-infrared spectroscopy (NIRS) and computed<a href="https://solaci.org/en/2021/04/16/the-future-of-prevention-stenting-vulnerable-fractional-ffr-negative-lesions/" title="Read more" >...</a>